According to Taihe Biotech's official announcement, the company's 7.5 million newly issued ordinary shares from its cash capital increase will begin trading on November 17, 2026, with par value of NT$10 per share, totaling NT$75 million. On the same day, share payment certificates currently trading since October 20 will cease to trade. Following the registration change completion, the Taiwan Depository & Clearing Corporation will automatically convert payment certificates held in shareholders' securities accounts into ordinary share certificates, requiring no action from shareholders. Total listed shares after this increase will reach approximately 59.99 million shares.

View Source

Disclaimer: This content is for informational purposes only and does not constitute investment advice or encourage the buying or selling of crypto assets. It is intended to provide information about industry developments and is not directly related to the services offered by Gate TR. Although information obtained from third-party sources has been carefully reviewed, Gate TR assumes no responsibility for any errors or omissions. Crypto assets involve high risks and may experience significant price fluctuations. Before making any investment decisions, you should assess your financial situation and risk tolerance, conduct your own research, and make decisions independently.